Compare VRAX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | PAVM |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 41.1M |
| IPO Year | 2021 | 2015 |
| Metric | VRAX | PAVM |
|---|---|---|
| Price | $2.24 | $2.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.50 |
| AVG Volume (30 Days) | ★ 26.3K | 23.8K |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,000,000.00 |
| Revenue This Year | N/A | $132.39 |
| Revenue Next Year | N/A | $263.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.00 |
| 52 Week Low | $0.10 | $0.21 |
| 52 Week High | $13.19 | $28.44 |
| Indicator | VRAX | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | N/A |
| Support Level | $2.15 | N/A |
| Resistance Level | $3.01 | N/A |
| Average True Range (ATR) | 0.18 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 19.05 | 0.00 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.